Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 126,747

Document Document Title
WO/2017/202814A1
The present invention relates to methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons. The 10 inventors showed that interleukin 33 promotes axonal outgrowth ...  
WO/2017/204210A1
Provided is an oral pharmaceutical composition characterized by containing a medicinal ingredient (A), a hydrophobic liquid (B), a water-soluble macromolecular substance (C), and an excipient (D), but not containing a surfactant, wherein...  
WO/2017/205399A1
The present disclosure describes compositions and methods for treating at least one symptom of an anxiety disorder in a human subject. The compositions and methods employ a therapeutically effective amount of a compound of formula I (Com...  
WO/2017/201581A1
The present invention relates to new desferrioxamine B-based compounds that may be useful to treat neurodegenerative diseases, to their preparation, and to compositions including the compounds. The present invention also relates to the u...  
WO/2017/204231A1
In brain dysfunction induced by brain hemorrhage or ischemia, it is needed to treat causative disease, i.e., hemorrhage or ischemia, and it is also needed to promote the protection or regeneration of nerve cells or the like that are dama...  
WO/2017/204321A1
The present invention provides a heat shock protein expression inducing agent, more specifically, a heat shock protein expression inducing agent containing a compound represented by formula (I) or a salt thereof. (In the formula, R repre...  
WO/2017/199042A1
The present invention provides an inhibitor of DNA damage signalling and repair for use in treating or preventing a neurological pathology and a neuro-regenerative compound comprising an inhibitor of DNA damage signalling and repair atta...  
WO/2017/199070A1
The present invention relates to a combination of pure 5-HT6 receptor antagonist, acetylcholinesterase inhibitor and NMDA receptor antagonist. Also, the present invention provides pure 5-HT6 receptor (5-HT6R) antagonists, or the pharmace...  
WO/2017/201069A1
The present invention provides chimeric compounds of formula (II) that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CKl-alpha activity and cell-cell ad...  
WO/2017/200953A1
Disclosed herein are methods for treating a human subject having a disease associated with an increased level of apoptosis using a nitroxide. Further disclosed are methods for treating a human subject in need of a reduced expression leve...  
WO/2017/199755A1
Provided is a drug that has excellent effect of preventing and/or treating dementia. The drug comprises a carbostyril derivative represented by formula (1) [wherein: R represents a cycloalkyl group; A represents a lower alkyl group; and ...  
WO/2017/201283A1
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally available formulations and other phar...  
WO/2017/197791A1
A Radix Polygoni Multiflori and Fructus Lycii liquor, consisting of the components of: 150 g of Radix Polygoni Multiflori, 80 g of Radix Rehmanniae Preparata, 100 g of Fructus Lycii, 30g Rhizoma Polygonati, 30 g of Radix Angelicae Sinens...  
WO/2017/198346A1
The present invention is relates to a compound of formula (I), wherein X1, X2 andX3 are, independently of each other, N or CH; with the proviso that at least two of X1X2andX3 areN; Y is N or CH; R1 and R2 are independently of each other ...  
WO/2017/198224A1
Provided is a pharmaceutical composition of remimazolam. In particular, provided is a pharmaceutical composition comprising remimazolam or a pharmaceutically acceptable salt thereof and a hydroxyethyl starch and/or a monosaccharide compo...  
WO/2017/199140A1
The invention relates to a method and a pharmaceutical composition of a combination of tramadol-etoricoxib hydrochloride for the treatment of pain, the production method of which is based on two active ingredients consisting of granules ...  
WO/2017/199976A1
The present invention addresses the problem of providing a novel use of pluripotent stem cells (Muse cells) for medical purposes in regenerative medicine. The present invention provides a cell preparation and a pharmaceutical composition...  
WO/2017/198276A1
The application relates to synthetic compositions containing one or more human milk oligosaccharides for treating serotonin and/or tryptophan dysregulation.  
WO/2017/201224A1
The present invention is a new controlled drug system that can be used for targeting non-invasive neuromodulation enabled by focused ultrasound gated release of one or more small molecule neuromodulatory agents.  
WO/2017/197555A1
Provided are certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R1, R3, R4a, R5a, R5b, R6, and the subscript t are described herein. The compounds or their pharmaceutically a...  
WO/2017/198180A1
The present invention provides a fluorine-containing triazolopyridine represented by formula (I) and a racemate, R-stereoisomer, S-stereoisomer, pharmaceutically acceptable salt, or mixture thereof. The triazolopyridine can be used as a ...  
WO/2017/199071A1
The present invention relates to pure 5-HT6 receptor antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitors and their use in the treatment of cognitive disorde...  
WO/2017/201285A1
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations a...  
WO/2017/200700A1
Provided herein are methods for treating surgical incisional pain or wound pain in a subject using disclosed compositions comprising an anticonvulsant agent and a biodegradable carrier, wherein the agent is incorporated within the biodeg...  
WO/2017/201468A1
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or condit...  
WO/2017/200391A1
The present invention relates to compositions including L-theanine, proanthocyanidin(s); and a catechin selected from the group consisting of epigallocatechin gallate, epigallocatechin, epicatechin gallate, epicatechin and combinations t...  
WO/2017/199090A1
The present invention provides a pharmaceutical composition that includes a neutral carrier treated with energy proportional to biopotential of human brain or nervous tissue. Preferably, the neutral carrier is obtained from initial liqui...  
WO/2017/199072A1
The present invention relates to pure 5-HT6 receptor antagonist or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to NMDA receptor antagonist and their use in the treatment of cognitive disorders. The i...  
WO/2017/198164A1
Provided in the present invention are uses of a compound as represented by formula I in preparing a stem cell apoptosis antagonist. Also provided are uses of the compound as represented by formula I in preparing a medicament for preventi...  
WO/2017/201364A1
Disclosed herein are a method for improving cognition in an individual having findings consistent with a cognitive impairment, and a method of enhancing cognition in an individual. The methods include administering a therapeutically effe...  
WO/2017/199014A1
The present invention relates to the use of c-Src inhibitors for the mitigation of side-effects associated with opioid analgesia and in particular for the mitigation of opioid tolerance in human and veterinary medicine.  
WO/2017/197463A1
The present invention relates to compounds and their uses. In particular, to compounds that inhibit endosomal protease-activated receptor-2 (PAR2) signaling and their use in the treatment of pain.  
WO/2017/198862A1
Methods of treating sepsis induced acute brain dysfunction (SiBD), comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. Methods of reducing sepsis mortality, comprising administering ...  
WO/2017/199041A1
The present invention provides vectors for delivering to a cell, or expressing in a cell, a therapeutic RNA that is capable of reducing expression of a target gene. Compositions comprising the vectors and comprising the therapeutic RNAs ...  
WO/2017/200863A1
The present invention provides N-[3-[2-Amino-5-(1,1-difluoroethyl) -4,4a,5,7-tetrahydrofuro[3,4-d][1,3]oxazin-7a-yl]-4-fluoro-p henyl]-5- (trifluoromethyl)pyridine-2-carboxamide, i.e. the compound of Formula I: [Formula should be inserte...  
WO/2017/193573A1
A pharmaceutical composition for treating an ischemic stroke, and a preparation method and application thereof. The pharmaceutical composition comprises: 3-12 parts by weight of NADPH, and 0.5-8 parts by weight of an acetovanillone.  
WO/2017/195781A1
Provided is a method for reducing the infectiousness of abnormal prion proteins. In this method for reducing the infectiousness of abnormal prion proteins, abnormal prion proteins are brought into contact with functional mineral water th...  
WO/2017/195224A1
The present invention concerns Rho GTPase activating bacterial toxins for use in treatment of cognitive impairment and neurodegenerative diseases such as Parkinson's disease by topical ocular, nasal or enteral administration, wherein sai...  
WO/2017/194586A1
The present invention relates to agents activating CD47 and their use in the treatment of inflammation, in particular non-resolving low grade inflammation, characterized by chronic MP infiltration, such as age-related macular degeneratio...  
WO/2017/194551A1
There is provided for novel therapy of sleep apnea that involves administering the drug sultiame to the patient.  
WO/2017/196874A1
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating spinal muscular atrophy, comprising administering to a subject an inhibitor of the complement pathway.  
WO/2017/195897A1
A transdermal preparation comprising a phenylpiperazine derivative, an organic acid, an ester-type solvent and an organic sulfoxide.  
WO/2017/194068A1
The present invention relates to a bioactive sweet whey protein concentrate or composition for increasing e.g. cognitive functions particularly in young mammals such as pre-term or term infants, toddlers, children or young adults. The pr...  
WO/2017/196432A1
Provided herein are compositions, devices, kits and methods for the diagnosis and treatment of neurodegenerative diseases and disorders. Certain agents disclosed herein detect, inhibit, suppress, abrogate or modulate acute or chronic imm...  
WO/2017/197192A1
Provided herein are spirocycle compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions...  
WO/2017/197016A1
Disclosed is an improved composition characterized in containing a combination of melatonin and 5-HTP in a nasal administration for the rapid treatment of insomnia, anxiety, and related disorders in mammals, including humans. The present...  
WO/2017/193662A1
Crystal forms I and II of tasimelteon. Crystal form I: an X-ray powder diffraction spectrum using CuKα radiation and represented by a 2θ angle has diffraction peaks at least at 7.2º±0.2º, 7.9º±0.2º, 10.6º±0.2º, 14.4º±0.2º, ...  
WO/2017/194496A1
The present invention relates to 5-HT6 receptor antagonists for the treatment of Alzheimer's disease with comorbid apathy comprising administering an effective dose of a 5-HT6 receptor antagonist to improve or augment the effect of an ac...  
WO/2017/193870A1
Provided are compounds of formula (I), or a stereoisomer, mixture of stereoisomers, deuterated analog, tautomer, solvate or pharmaceutically acceptable salt thereof, compositions, method of making and uses thereof.  
WO/2017/195780A1
Provided is a method for restoring the three-dimensional structure of an abnormalized protein. A method for restoring the three-dimensional structure of an abnormalized protein to a normal structure by bringing a functional mineral water...  

Matches 51 - 100 out of 126,747